It also signed a development deal with Quest Diagnostics to create a blood test for early-stage, non-small-cell lung cancer.

[18] In 2016, a study was published that used the SomaLogic system to identify nine biomarker proteins that could predict the risk of a second heart attack in those who have suffered a previous cardiovascular event.

[24] In 2018, SomaLogic teamed up with the Leeds Centre for Personalised Health and Medicine to test the SomaScan platform in clinical studies in the UK.

[25] That same year, SomaLogic also began to package its insights as diagnostic information for sale to other companies, focusing on proteomic data.

[27] Also that year, SomaLogic began commercially offering health information tests on the SomaScan Platform to prescribing physicians in Colorado.